Answers are grounded in this paper and cite their sources.
Experiments demonstrate SRT-1720 sensitizes leukemic T-cells to drugs, suggesting enhanced chemotherapy efficacy.
SRT-1720 induces oxidative stress and apoptosis in leukemic lymphocytes through SIRT1-independent pathway(s). In contrast, it enhances antioxidant defense in normal lymphocytes through a SIRT1-dependent pathway. These findings highlight the potential of SRT-1720 as an adjuvant to chemotherapy in T-ALL, particularly in drug combinations demonstrating strong synergism, which may allow dose reduction and decreased toxicity.
No takes yet. Share an insight, caveat, or question.
Ivanova et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: